Larimar Therapeutics
LRMR
68 hedge funds and large institutions have $174M invested in Larimar Therapeutics in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 4 closing their positions.
500% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 4
92% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 12
42% more funds holding
Funds holding: 48 → 68 (+20)
9% more capital invested
Capital invested by funds: $160M → $174M (+$13.8M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less ownership
Funds ownership: 89.81% → 88.82% (-1%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$3.28M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$2.42M |
| 3 |
FAM
Fred Alger Management
New York
|
+$1.49M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.34M |
| 5 |
Millennium Management
New York
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
CHI Advisors
New York
|
-$3.8M |
| 2 |
CC
Commodore Capital
New York
|
-$3.1M |
| 3 |
PA
Perceptive Advisors
New York
|
-$3.03M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$2.54M |
| 5 |
Morgan Stanley
New York
|
-$2.49M |
LRMR Hedge Fund Activity: Q1 2023 in Review
68 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q1 2023, worth a combined $174M — up 8.6% from $160M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new LRMR positions and 4 closed out — a net gain of 20 holders — while 23 added to existing stakes and 12 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $3.28M. The largest seller was CHI Advisors, cutting an estimated $3.8M.
- 68 institutional investors held Larimar Therapeutics (LRMR) as of Q1 2023, up from 48 in Q4 2022.
- Funds reported $174M of Larimar Therapeutics stock for Q1 2023, up 8.6% quarter-over-quarter.
- 24 funds opened new Larimar Therapeutics positions in Q1 2023 and 4 closed out, a net change of +20 holders.
- The largest Larimar Therapeutics buyer in Q1 2023 was JP Morgan Chase, an estimated $3.28M added.
- The largest Larimar Therapeutics seller in Q1 2023 was CHI Advisors, an estimated $3.8M sold.
Based on aggregated 13F filings for Q1 2023.